Attana received its first order from the customer in March 2018 and following a successful first collaboration the same customer has since several contract research project. 

"We are looking forward to continue working closely with the customer and I see this order as yet another strong validation of our core offering." - Teodor Aastrup, CEO of Attana, comments. 

For more information, please contact: 

Niklas Carlsson, COO 
niklas.carlsson@attana.com   (niklas.carlsson@attana.com%C2%A0%0b)
+46 (0)73 867 67 62 

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana 

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com